[go: up one dir, main page]

FI20115165A0 - Terapeuttisia ja diagnostisia menetelmiä - Google Patents

Terapeuttisia ja diagnostisia menetelmiä

Info

Publication number
FI20115165A0
FI20115165A0 FI20115165A FI20115165A FI20115165A0 FI 20115165 A0 FI20115165 A0 FI 20115165A0 FI 20115165 A FI20115165 A FI 20115165A FI 20115165 A FI20115165 A FI 20115165A FI 20115165 A0 FI20115165 A0 FI 20115165A0
Authority
FI
Finland
Prior art keywords
therapeutic
diagnostic methods
kit
prevention
treating
Prior art date
Application number
FI20115165A
Other languages
English (en)
Swedish (sv)
Inventor
Ulf Lindahl
Jin-Ping Li
Fredrik Noborn
Original Assignee
Polysackaridforskning I Uppsala Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polysackaridforskning I Uppsala Ab filed Critical Polysackaridforskning I Uppsala Ab
Priority to FI20115165A priority Critical patent/FI20115165A0/fi
Publication of FI20115165A0 publication Critical patent/FI20115165A0/fi
Priority to CN201280019063.0A priority patent/CN103492882B/zh
Priority to JP2013553968A priority patent/JP2014510907A/ja
Priority to US14/000,683 priority patent/US20150037341A1/en
Priority to EP12704819.7A priority patent/EP2678689A1/en
Priority to PCT/EP2012/052919 priority patent/WO2012113784A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727Heparin; Heparan
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/70Mechanisms involved in disease identification
    • G01N2800/7047Fibrils-Filaments-Plaque formation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI20115165A 2011-02-21 2011-02-21 Terapeuttisia ja diagnostisia menetelmiä FI20115165A0 (fi)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FI20115165A FI20115165A0 (fi) 2011-02-21 2011-02-21 Terapeuttisia ja diagnostisia menetelmiä
CN201280019063.0A CN103492882B (zh) 2011-02-21 2012-02-21 诊断甲状腺素运载蛋白淀粉状变性的方法及其试剂盒
JP2013553968A JP2014510907A (ja) 2011-02-21 2012-02-21 診断方法及び治療方法
US14/000,683 US20150037341A1 (en) 2011-02-21 2012-02-21 Diagnostic and Therapeutic Method
EP12704819.7A EP2678689A1 (en) 2011-02-21 2012-02-21 Diagnostic and therapeutic methods
PCT/EP2012/052919 WO2012113784A1 (en) 2011-02-21 2012-02-21 Diagnostic and therapeutic methods

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20115165A FI20115165A0 (fi) 2011-02-21 2011-02-21 Terapeuttisia ja diagnostisia menetelmiä

Publications (1)

Publication Number Publication Date
FI20115165A0 true FI20115165A0 (fi) 2011-02-21

Family

ID=43629837

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20115165A FI20115165A0 (fi) 2011-02-21 2011-02-21 Terapeuttisia ja diagnostisia menetelmiä

Country Status (6)

Country Link
US (1) US20150037341A1 (fi)
EP (1) EP2678689A1 (fi)
JP (1) JP2014510907A (fi)
CN (1) CN103492882B (fi)
FI (1) FI20115165A0 (fi)
WO (1) WO2012113784A1 (fi)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
TWI786505B (zh) * 2015-01-28 2022-12-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
US11028128B2 (en) 2016-06-30 2021-06-08 The Regents Of The University Of California Inhibition of the aggregation of transthyretin by specific binding of peptides to aggregation-driving segments
MX2020003043A (es) 2017-10-06 2020-10-05 Prothena Biosciences Ltd Métodos para detectar transtiretina.
MX2020003041A (es) * 2017-10-06 2020-10-05 Prothena Biosciences Ltd Anticuerpos anti-transtiretina.
CN111433223B (zh) 2017-11-29 2024-08-27 诺和诺德A/S(股份有限公司) 抗甲状腺素运载蛋白单克隆抗体的冻干制剂
CN116726148B (zh) * 2023-08-02 2023-11-14 中国中医科学院针灸研究所 一种具有镇痛作用的化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958883A (en) * 1992-09-23 1999-09-28 Board Of Regents Of The University Of Washington Office Of Technology Animal models of human amyloidoses
EP2074223A4 (en) * 2006-09-15 2010-03-10 Foldrx Pharmaceuticals Inc TEST PROCEDURE FOR THE DETECTION OF PROTEINS IN THE NATIVE CONDITION AND FOR THE IDENTIFICATION OF THE STABILITY OF PROTEINS IN THE NATIVE CONDITION MODULATING COMPOUNDS

Also Published As

Publication number Publication date
US20150037341A1 (en) 2015-02-05
CN103492882A (zh) 2014-01-01
WO2012113784A1 (en) 2012-08-30
CN103492882B (zh) 2016-06-22
JP2014510907A (ja) 2014-05-01
EP2678689A1 (en) 2014-01-01

Similar Documents

Publication Publication Date Title
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
BR112014021104A2 (pt) métodos e composições para o tratamento da doença de huntington
AU2011328009A8 (en) Compounds and methods for treating pain
MX343135B (es) Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
BR112014010299A2 (pt) composição para prevenir e tratar doenças da cavidade oral; método de prevenção e tratamento de doenças da cavidade oral; e uso da composição
EA201290919A1 (ru) Индазольные соединения и их применение
MY169328A (en) Compositions for the treatment of dry eye
EA201490748A1 (ru) Лечение рассеянного склероза комбинацией лахинимода и финголимода
FI20115165A0 (fi) Terapeuttisia ja diagnostisia menetelmiä
EP2726511A4 (en) COMPOSITIONS, USES AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS AND DISEASES
MX382162B (es) Combinaciones farmacéuticas de un inhibidor de enzima hdac con un inhibidor de proteasoma, y su uso en el tratamiento de cáncer.
UA117096C2 (uk) Поліпептид, що зв'язується з c5 комплементу людини
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
EA201491500A1 (ru) Способы лечения фиброза
TW201613578A (en) Pharmaceutical combinations
CY1120877T1 (el) Συνθεσεις και μεθοδοι για την αντιμετωπιση της κοιλιοκακης
UA114417C2 (uk) Інгібітори iap
PH12016502352A1 (en) Pharmaceutical composition
EP4272839A3 (en) Treatment of allergic rhinitis using a combination of mometasone and olopatadine
BR112013010136A2 (pt) vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma
EA201591507A1 (ru) Лечение рассеянного склероза лахинимодом
BR112013017184A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para evitar, tratar ou melhorar doenças
EP2563120A4 (en) METHOD, COMPOSITIONS AND KITS FOR PROVIDING THERAPEUTIC TREATMENT
EA201491581A1 (ru) Везикулярные композиции

Legal Events

Date Code Title Description
FD Application lapsed